Escalon Medical Corp, a niche player in ophthalmic ultrasound and surgical products, reported modest revenue growth and a return to profitability in fiscal 2025 following prior losses. This improvement was driven by product mix shifts favoring Trek’s offerings and global sales stability, though international sales fell slightly. Despite positive operating income and cash flow, the company grapples with significant accumulated deficits and working capital constraints that raise questions about its going concern status. Elevated tariffs imposed mid-2025 pose risks to supply chain cost inflation and international demand. On the innovation front, R&D investments increased to support product enhancements but remain moderate relative to scale. Capital expenditures sharply decreased in FY2025, reflecting cautious spending. With no dividends or buybacks reported, Escalon prioritizes liquidity preservation amid competitive pressures from larger device manufacturers and emerging optical imaging techniques.